Committed to improve the lives of patients with amyloid-related diseases
Amyl Therapeutics is a preclinical-stage biotech company developing Pan-Amyloid Immunotherapy (PAI), a universal treatment for amyloid-mediated diseases.
Amyloid aggregates are implicated in over 30 disorders, including high-need neurodegenerative diseases like Alzheimer’s and Parkinson’s and rare conditions like AL amyloidosis.

Our candidates selectively target the conformation present in all amyloid aggregates, making them effective against all amyloid-mediated diseases.

PAI clears amyloid aggregates in late stages and inhibits their formation in early stages, supporting both therapeutic and preventive applications. This dual action and universal applicability can revolutionize the lives of patients with amyloid-related diseases.

40 years ago

Initial report of the purification and characterization of amyloid-β as pathological factor in Alzheimer diseases.
1984. Biochem Biophys Res Commun.
May 16;120(3):885-90.

Today

Substantial and consistent evidence supporting the clinical effectiveness of monoclonal antibodies aimed at amyloid-β is finally emerging.
2024. Review Eur J Neurol.
Feb;31(2) :e16049
Our approach is driven by an experienced team with extensive drug development expertise, and productive collaborations with world-class advisors and partners.

Our team members

Dr Pierre Vandepapelière

MD, PhD

CEO, CMO, Founder

Turn card around by clicking
Read bio

Dr Pierre Vandepapelière

Pierre Vandepapelière has been Amyl's co-founder, CEO, and CMO since 2020. Previously, he was CEO of Imcyse from 2014 to 2019, transforming the company into a rapidly growing biotech and raising €35M in Series B funding. During the COVID-19 pandemic, he contributed to several vaccine projects, including creating Astrivax. Pierre has also held leadership roles at Neovacs and GlaxoSmithKline. He holds a medical degree and a PhD. In his spare time, Pierre enjoys sailing, photography, and birdwatching.

Logo Linked In

Damien Toulorge

PhD

CSO

Turn card around by clicking
Read bio

Damien Toulorge

Before joining Amyl, Damien worked as a Project Lead at Pharnext, focusing on neurodegenerative diseases, including Parkinson’s, Alzheimer’s, and ALS. He co-founded and served as CSO of Encefa for eight years, leading the development of a monoclonal anti-CD38 antibody for ALS. Damien holds an MSc in Biochemistry and Genetics from Agrocampus Rennes and a PhD in Neurosciences from Paris Sorbonne. He is currently the CSO of Amyl. Damien is also a fan of hard rock and metal music.

Logo Linked In

Julie Goemaere

PHD

RD Director

Turn card around by clicking
Read bio

Julie Goemaere

Julie Goemaere joined Amyl Therapeutics as Director of Research and Development in early 2023. She has over 10 years of experience in scientific and management roles in the biotech sector. After her thesis on oxidative stress and neurodegeneration, she developed bioassays at GSK Vaccines and became a project manager focused on clinical research disclosure. At Thermo Fisher Scientific, she led upstream process development for viral vectors in gene therapy. Julie holds a PhD in Biological Sciences from UCLouvain, Belgium. In her current role, Julie is leading the R&D team with fervor, while in her private life, she likes to unwind in close contact with nature.

Logo Linked In

Christophe Mathieu

Corporate & Tax Lawyer

CFO, Legal and Financial Support

Turn card around by clicking
Read bio

Christophe Mathieu

Christophe holds three Master's degrees in Law, European Law, and Tax Management. He is a Chartered Accountant and Tax Advisor with expertise in corporate governance. Christophe began his career as an M&A lawyer in Brussels before moving to a role as a Tax Advisor at KPMG Belgium. He later founded Financial Way, where he served as CEO and CFO for more than 15 life science startups. Passionate about wine, skiing, and tranquility, Christophe even completed a marathon and enjoys long commutes by train or bike, preferring them over driving.

Logo Linked In

Koen Vanhalst

PhD

IP Consultant

Turn card around by clicking
Read bio

Koen Vanhalst

Koen Vanhalst holds a PhD in Biotechnology from the University of Ghent and has experience as an Examiner at the European Patent Office. He qualified as a European Patent Attorney in 2009 and a Belgian Patent Attorney in 2011, becoming a partner at De Clercq & Partners in 2017. In 2023, he earned a Certificate in Patent Litigation in Europe. Koen teaches Intellectual Property at Ghent Universityand is active in organizations like AIPPI Belgium and the Belgian Council for Intellectual Property. At Amyl, he develops IP strategy while enjoying traveland cultural exploration in his free time.

Logo Linked In

Karine Goraj

PhD

Former CSO, strategic advisor

Turn card around by clicking
Read bio

Karine Goraj

Karine worked for over 20 years in the R&D department at GSK Vaccines, holding key positions such as Vaccine Project Leader and Head of Discovery Performance Unit at the GSK RD Center in Italy. She has a PhD in Biochemistry from Liege University, specializing in Protein Engineering. From 2021 to 2024, she served as CSO of Amyl, overseeing preclinical development. She now serves as a Strategic Advisor. Karine enjoys spending time with her family, attending classic and rock concerts, and taking trips in her van to explore nature.

Logo Linked In

Our board members

Florent Gros

Chairman, Founder

Turn card around by clicking
Read bio

Florent Gros

Florent Gros has has held various leadership positions in venture, intellectual property and business transactions at Nestlé, Pasteur Merieux Connaught and Novartis in Switzerland, Europe and North America. Florent has been an active investor for Novartis Venture Funds, seeding companies, serving as director and advisor, sometimes serving as ad. interim CEO, for biotech and medtech companies such as Adicet Bio, Anokion, Binx Health, Covagen, Evolva, Gensight Biologics, Inflazome, Merus, Okairos, Oculis, Vivet Therapeutics.

Logo Linked In

Valérie Calenda

Merieux Equity Partners

Turn card around by clicking
Read bio

Valérie Calenda

Valérie Calenda started her career as research scientist in Hematology and Virology at the Institut National de la Recherche Médicale (INSERM). After collaborating on a French/US research program relating to HIV at Davis University, she joined Transgene S.A., an affiliated company of Institut Mérieux, focusing on gene Therapy and immunotherapy. She then led a spin-off project in cardio-vascular therapeutic area before collaborating with a Paris based seed Venture Capital firm. Valérie also managed several biotech clinical-stage product developments within the infectious diseases and oncology disease areas, from pre-IND to Phase 2. This led her to manage both in-licensing and out-licensing activities, including global license agreement and alliance management with Hoffman La Roche, acquisition of biotech assets in Europe and in the US.

Logo Linked In

Hélène Sabatel

Investment Manager

Turn card around by clicking
Read bio

Hélène Sabatel

Helene has a PhD in molecular biology during which she studied the signaling pathways activated in response to chemotherapeutic treatments in cancer cells. She also completed a master’s degree in management. After an experience in customer support at Eurogentec, she joined the technology transfer office of the University of Liege for more than 8 years where she managed Intellectual property, negotiated collaboration and license agreements with companies and support the setting up of spin-offs. Afterwards, she joined Noshaq as a Life Sciences Investment Manager following up on several Noshaq’s holdings in biotech companies.

Logo Linked In

Kenneth A. Buckfire

President

Turn card around by clicking
Read bio

Kenneth A. Buckfire

Kenneth A. Buckfire is the President and co-Founder of Miller Buckfire & Co. During his 30 year career in restructuring he has advised clients in a broad range of industries including oil & gas, oilfield services, homebuilding and real estate, merchant power, electric utilities, broadcasting, media, telephone and data services, shipping, governments and government agencies. In addition to co-founding Miller Buckf ire in 2002 (acquired by Stifel Financial in 2012), he co-founded Marblegate Asset Management in 2008 which was sold when Stifel Financial acquired Miller Buckfire in 2012.

Logo Linked In

Dr Pierre Vandepapelière

CEO, CMO, Founder

Turn card around by clicking
Read bio

Dr Pierre Vandepapelière

Pierre Vandepapelière has been Amyl's co-founder, CEO, and CMO since 2020. Previously, he was CEO of Imcyse from 2014 to 2019, transforming the company into a rapidly growing biotech and raising €35M in Series B funding. During the COVID-19 pandemic, he contributed to several vaccine projects, including creating Astrivax. Pierre has also held leadership roles at Neovacs and GlaxoSmithKline. He holds a medical degree and a PhD. In his spare time, Pierre enjoys sailing, photography, and birdwatching.

Logo Linked In